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Dual antiplatelet therapy reduces ischemic events in cardiovascular disease, but increases bleeding risk. 
Thrombin receptors PAR1 and PAR4 are drug targets, but the role of thrombin in platelet aggregation remains 
largely unexplored in large populations. We performed a GWAS of platelet aggregation in response to full-
length thrombin, followed by clinical association analyses, Mendelian Randomization, and functional 
characterization including iPSC-derived megakaryocyte and platelet experiments. We identified a single 
sentinel variant in the GRK5 locus (rs10886430-G, P=3.0x10-42) associated with increased thrombin-induced 
platelet aggregation (ß=0.70, SE=0.05). We show disruption of platelet GRK5 expression by rs10886430-G is 
associated with enhanced platelet reactivity. The proposed mechanism of a GATA1-driven megakaryocyte 
enhancer is confirmed in allele-specific experiments. Utilizing further data, we demonstrate the allelic effect is 
highly platelet- and thrombin-specific, and not likely due to effects on thrombin levels. The variant is 
associated with increased risk of cardiovascular disease outcomes in UK BioBank, most strongly pulmonary 
embolism. The variant associates with increased risk of stroke in the MEGASTROKE, UK BioBank and FinnGen 
studies. Mendelian Randomization analyses in independent samples support a causal role for rs10886430-G 
increasing risk for stroke, pulmonary embolism, and VTE through its effect on thrombin-induced platelet 
reactivity. We demonstrate that GRK5 promotes platelet activation specifically via PAR4 receptor signaling. 
GRK5 inhibitors in development for heart failure and cancer could have platelet off-target deleterious effects. 
Common variants in GRK5 may modify clinical outcomes with PAR4 inhibitors, and upregulation of GRK5 





Activated platelets provide the link between inflammation, thrombosis, and atherosclerotic 
cardiovascular disease 1. Platelet reactivity is highly heritable 2; 3, but the limited number of previously 
identified loci explain only a small portion of the estimated heritability 4. Despite thrombin being the principal 
enzyme of hemostasis and viewed as the strongest platelet agonist 5, the genetics of thrombin-induced 
platelet reactivity is not well understood and heretofore has not been investigated on a genome-wide scale. 
Many of thrombin’s cellular effects are initiated by protease-activated receptors (PARs) which are G protein-
coupled receptors (GPCRs) 6. PAR1 (MIM: 187930) and PAR4 (MIM: 602779) are the receptors primarily 
responsible for mediating the effects of thrombin in human platelets 5. 
Dual antiplatelet therapy (DAPT) reduces the occurrence of both stent-related and spontaneous 
myocardial infarction (MI) after acute coronary syndrome (ACS), but with concomitant increase in bleeding 
risk 7. Thus, there is a need for milder DAPT targets in order to maintain or increase efficacy while reducing 
bleeding, given the narrow therapeutic window of most antiplatelet treatments8. Development of more 
effective strategies could potentially expand anti-platelet therapy into primary prevention where it generally is 
not recommended due to bleeding risks. Given their role in platelet biology PAR1 and PAR4 have both been 
the focus of antithrombotic drug development. Targeting PAR1, the high affinity thrombin receptor, led to 
vorapaxar, approved for preventing thrombotic events in patients with MI when used in combination with 
standard-of-care DAPT 9. Of limited clinical utility vorapaxar is associated with increased risk of major bleeding 
events 9 where the mortality risk due to bleeding can be comparable or greater than that due to MI 10. 
Compared to PAR1 there is evidence that targeting PAR4 is associated with a lower bleeding risk and can 
achieve an effective antithrombotic profile, though large trials of PAR4 inhibition are still lacking 11-13. 
While prospective studies have demonstrated the association of platelet function with cardiovascular 
disease (CVD) events in patients with established cardiovascular disease, there is less existing evidence that 
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platelet function predicts CVD or CVD outcomes in the healthy population 14. Clinical trials have demonstrated 
a relationship between high on-treatment platelet reactivity and adverse clinical ischemic events, but tailoring 
therapy based on platelet reactivity remains uncertain15. Platelet function traits remain relatively unexplored 
in large populations, in particular for thrombin and PAR1/PAR4 platelet activation. In order to address this 
broad knowledge gap—to discover genes that may mediate CVD or bleeding risk, classify treatment 
subpopulations or suggest new therapeutic targets, we performed the first genome-wide association study 
(GWAS) of thrombin-induced platelet aggregation.   
 
Subjects and Methods 
PARTICIPANTS AND GENOMEWIDE ANALYSES 
We conducted and present analyses from the following methodological approaches: 1) a GWAS of platelet 
thrombin activation, 2) platelet and other cell and tissue eQTL analyses, including Mendelian Randomization 
(MR), for our lead locus, and signal co-localization analyses, 3) two sample MR for cardiovascular disease 
outcomes from multiple Consortia and biobanks, 4) integration of megakaryocyte and other epigenetic data at 
our lead locus, 5) site-directed mutagenesis and regulatory enhancer assays in 3 cell backgrounds, and 6) iPSC-
derived megakaryocyte, and platelet, siRNA and chemical inhibitor experiments to dissect functional effects 
on platelets. The samples and resources utilized are described in Table S1. The demographic characteristics of 
the GWAS study sample are shown in Table S2.  
The Caerphilly Prospective Study assessed platelet aggregation induced by full-length thrombin (0.056 
units/mL, Sigma Aldrich) in middle aged males using light transmission aggregometry (LTA) 16. All participants 
provided written informed consent. Genotyping of 1248 samples was performed with the Affymetrix UK 
BioBank Axiom array. Following sample and genotyping quality control, imputation was done on 1184 samples 
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using the Haplotype Reference Consortium (HRC) 1.1 panel. We conducted a GWAS using a linear mixed model 
adjusting for age and medication usage. A significance threshold of P < 7 x 10-9 was adopted to account for all 
variants tested. Conditional analyses adjusting for the strongest peak SNP in GRK5 (MIM: 600870), 
rs10886430, were conducted by adding SNP dosage as a covariate to the base model. Our methods for 
platelet aggregation, genotyping, quality control procedures, imputation, and GWAS are further described in 
the Supplementary Appendix. 
 
CAUSAL ANALYSIS AND MULTI-TRAIT COLOCALIZATION FOR GRK5 LOCUS 
Testing for causal association with expression quantitative trait loci (eQTL) was conducted with the use of the 
platelet RNA and expression 1 (PRAX1) platelet eQTL dataset 17. We investigated whether thrombin-induced 
aggregation and platelet cell traits share a common association signal at the GRK5 locus by performing a co-
localization analysis with quantitative traits derived from multiple blood cell lineages: platelets (mean platelet 
volume, MPV; platelet count, PLT; platelet distribution width, PDW), red blood cell count (RBC), and white 
blood cell count (WBC) 18. Furthermore, we conducted similar genetic colocalization analyses for the GRK5 
locus using genome-wide study data for thrombin generation potential 19, platelet aggregation to ADP, 
collagen and epinephrine 4; 20, and eQTLs from 44 cells and tissues from the GTeX Project version 7, five white 
blood cell types and platelets from the CEDAR project 21, and aortic endothelial cells 22.  Two sample 
Mendelian Randomization (MR) analysis was conducted using the rs10886430-G allele as the genetic 
instrument and thrombin-induced platelet aggregation as exposure in separate analyses for nine pulmonary, 
stroke, or heart disease outcomes from the UK BioBank 23, four stroke outcomes from the MEGASTROKE 
consortium 24, and cardiovascular disease codes in the FinnGen Biobank (version 4)25. Only this SNP was used 
in MR analyses because in conditional analyses of chromosome 10 this was the only independently significant 
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SNP associated with thrombin reactivity or platelet GRK5 expression levels. Details regarding these analyses 
are given in the Supplementary Appendix. 
 
REGULATORY FUNCTION 
We integrated epigenetic regulatory maps of chromatin accessibility, enhancer RNA (eRNA), histone marks, 
enhancer elements, and DNA-binding proteins assessed in megakaryocyte-erythroid lineage models 
(ENCODE)26; 27 and cultured primary megakaryocytes (BLUEPRINT) to annotate potential functional impacts of 
the intronic GRK5 rs10886430 variant 28; 29. Protein network analysis of transcriptional regulators that bind the 
rs10886430 variant was performed with STRING 10.5. We used site-directed mutagenesis to investigate the 
impact of the rs10886430 variant on enhancer activity in vitro in GATA1- (MIM: 305371) and GATA2- (MIM: 
137295) overexpressing HEK293 cells, as well as HUVEC and K562 cells. Details regarding the data integration, 
network analysis, enhancer reporter luciferase assays and conditional overexpression of GATA1 and GATA2 
are provided in the Supplementary Appendix. 
 
PLATELET FUNCTION siRNA AND INHIBITOR EXPERIMENTS 
The role of GRK5 in platelet function was assessed by siRNA as well as pharmacologic inhibition of GRK 
activity. Immortalized megakaryocyte progenitor cell lines (imMKCLs) were generated from human induced 
pluripotent stem cells and maintained as previously described 30.  For siRNA experiments imMKCLs were 
transfected with GRK5 or control eGFP siRNA for 48 h, then analyzed by qRT-PCR and in vitro flow cytometric 
analysis of platelet function(via P-selectin and PAC-1) following stimulation with either 20 M ADP plus 20 M 
thrombin receptor-activating peptide 6 (TRAP-6 that activates platelets via PAR1) or control. Pharmacologic 
inhibition of GRK activity was investigated with the pan-GRK inhibitor CCG215022 (MedChemExpress) which 
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exhibits nanomolar IC50 values against both GRK2 as well as GRK5 and selectivity against PKA31. Platelet-rich 
plasma (PRP) samples obtained from healthy donors (n=3) were treated with 0.78M CCG215022 or DMSO 
vehicle for 45 min prior to stimulation with increasing concentrations of one of three platelet agonists: PAR4 
Activating Peptide (PAR4-AP, 1, 20, 50 M), TRAP-6 (1, 10, 20 M), ADP (1, 10, 20 M) or vehicle control 
followed by flow cytometric analysis of platelet function (via P-selectin and PAC-1). Details regarding the siRNA 
experiments in imMKCL, GRK inhibition in PRP samples, and platelet function assessment by flow cytometry 
are provided in the Supplementary Appendix. 
 
Results 
We performed a GWAS of thrombin-induced platelet aggregation in the Caerphilly Prospective Study including 
>7.75 million common and low-frequency (minor allele frequency (MAF) > 0.01) SNPs imputed via the HRC 
panel. There was no evidence for inflation of test statistics ( = 1.005) (Figure S1A). We observed 17 variants 
that surpassed the genome-wide significance threshold (P < 7 x 10-9) for association with thrombin-induced 
aggregation, all localized to 10q26.11 (Figure 1A). Conditional analysis identified no additional signals 
independent of the sentinel variant located in the first intron of the GRK5 locus (GRK5, rs10886430, P = 3.0 x 
10-42), ~ 43-kb downstream from the transcription start site (TSS) within consensus intron 1 (Figure S1B, Table 
S3). The minor G allele (MAF 0.136) of the GRK5 SNP was associated with increased platelet reactivity to 
thrombin (ß = 0.70, SE = 0.05; with other covariates fixed this is ~3.9% per allele increase in thrombin 
reactivity) (Figure 1B). Variance component analysis indicates this single variant explained 18.3% of variation 
in the thrombin phenotype. There was no significant population structure in Caerphilly, being overwhelmingly 
European ancestry based on principal components clustering with multi-ethnic samples in the UK BioBank 
(Figure S2). Likewise, we found little relatedness in Caerphilly with only n=303 having any 1st, 2nd or 3rd degree 
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relations. Inclusion of the genetic relatedness matrix in the GWAS accounted for this. Nonetheless, we 
conducted a sensitivity analysis removing the n=303 individuals and analyzing chromosome 10 and 
rs10886430 remained highly significant (P = 2.01 x 10-31), indicating the results are population associations 
rather than strong family effects. 
 
We next asked whether thrombin-induced aggregation and platelet, red and white cell count traits share a 
common association signal at the GRK5 locus. We performed a Bayesian test for co-localization between the 
Caerphilly thrombin GWAS and multiple blood cell lineage traits from the UK BioBank/INTERVAL study meta-
analysis 18, interrogating shared variants in an ~1.8 Mb independent linkage disequilibrium block containing 
the GRK5 lead SNP. We observed strong evidence for co-localization (posterior probability > 0.99) between 
thrombin reactivity and platelet cell traits (MPV, PLT, PDW) but not WBC or RBC, supporting the hypothesis a 
single variant affects these traits in platelets (Figure 2A). The GRK5 lead SNP (rs10886430) was identified as 
the shared, potentially causal variant in each case (Table S4). With the association limited to platelets, we next 
asked whether the rs10886430 variant affects platelet reactivity mediated by other agonists. We conducted 
GWAS on aggregation to ADP and Collagen in Caerphilly participants and performed colocalization analyses 
with the thrombin GWAS. No evidence of colocalization was observed between thrombin reactivity and either 
agonist (Table S5). Further, no colocalization was observed with aggregation to ADP, Collagen, or Epinephrine 
in the largest such GWAS published to date in independent cohorts 4 (Table S6). We next asked whether the 
effect on thrombin reactivity was limited to platelet activation or was also observed in thrombin generation 
potential traits which could indicate an effect mediated via thrombin levels. No colocalization was observed 




To determine potential regulatory impacts of the rs10886430 variant, we first examined its association with 
functional expression changes cataloged in the platelet-specific PRAX1 study eQTL dataset 17; 32. We utilized 
summary data-based Mendelian Randomization (SMR) analysis with the PRAX1 eQTL dataset to test for 
association between platelet gene expression and platelet reactivity to thrombin. We identified GRK5 as the 
only gene at a genome-wide significance level (ßSMR = -1.54, SESMR = 0.20, PSMR = 3.67 x 10-14) (Figure 2B, Table 
S8). Finding no evidence to suggest the SMR association could be due to genetic linkage (PHEIDI = 0.16), we 
concluded expression of GRK5 is associated with platelet reactivity driven by the rs10886430 variant. As 
predicted by our SMR analysis, the minor rs10886430-G allele is a strong cis-eQTL for decreased platelet GRK5 
expression (ßeQTL = -0.456, PeQTL = 8.27 x 10-20) in the PRAX1 study 17. We further replicated this strong GRK5 
eQTL in the independent CEDAR platelet dataset 21 (ßeQTL = -0.429, PeQTL = 1.11 x 10-20). To investigate the 
tissue specificity of the genetic effect of rs10886430-G on GRK5 expression we conducted co-localization 
analyses between the Caerphilly thrombin GWAS in the GRK5 locus and 51 tissue or cell types. We observed 
no evidence of co-localization between thrombin reactivity and GRK5 expression among 44 tissues profiled by 
the Genotype-Tissue Expression (GTEx) Project (Table S9), five other white blood cell types 21 (Table S10), or 
vascular endothelial cells 22 (Table S11). 
 
Having observed the strong association of rs10886430-G with lower GRK5 expression exclusively in platelets, 
we asked whether the genetic effect of the variant on platelet reactivity was further associated with relevant 
cardiovascular or cerebrovascular disease pathology. We utilized GWAS statistics for nine pulmonary, stroke, 
or heart disease diagnoses in the UK BioBank cohort. There was evidence for an association of rs10886430-G 
with several diagnoses, most strongly pulmonary embolism (OR = 1.25, SE = 1.03, P = 8.1 x 10-13) (Table S12).  
We performed 2-sample MR to test for a causal relationship between thrombin reactivity (exposure) and 
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disease outcome for the nine UK BioBank diagnoses. We observed strong, positive association between 
thrombin-induced platelet reactivity at the GRK5 locus and multiple disease outcomes, most significantly with 
diagnosis of pulmonary embolism (ORMR = 1.38 [1.26 – 1.52], PMR = 2.40 x 10-11), also with diagnoses of 
cerebral infarction (ORMR = 1.19 [1.08 – 1.32], PMR = 7.43 x 10-4) and acute myocardial infarction (ORMR = 1.14 
[1.07 – 1.21], PMR = 6.67 x 10-5), but not heart failure (ORMR = 1.04 [0.96 – 1.12], PMR = 0.39) (Figure 2C, Table 
S12). Next we investigated the rs10886430-G variant in stroke subtypes from MEGASTROKE 24, the cohorts of 
which are independent of UK BioBank. There was evidence for a stronger association in cardioembolic stroke 
(OR = 18.42, SE = 2.96, P = 6.16 x 10-4) than ischemic stroke (OR = 1.61, SE = 1.15, P = 2.29 x 10-4), and no 
association for large artery stroke (OR = 4.32, SE = 5.09, P = 0.39) (Table S13). In MR analyses we observed 
strong, positive association between thrombin-induced platelet reactivity at the rs10886430-G variant and 
cardioembolic stroke (ORMR = 64.36 [3.09 – 1340.44], PMR = 7.18 x 10-3), all stroke (ORMR = 1.79 [1.19 – 1.27], 
PMR = 7.69 x 10-4), and ischemic stroke (ORMR = 1.97 [1.22 – 1.33], PMR = 7.17 x 10-4 ), but not large artery stroke 
(ORMR = 10.24 [0.08 – 773.88], PMR = 0.37) (Table S13). Finally, the G allele was again associated with increased 
risk of multiple cardiovascular disease outcomes in the FinnGen study: DVT of lower extremities (ORMR = 1.25 
[1.11– 1.41], PMR = 2.28 x 10-4), ischemic stroke (ORMR = 1.15 [1.06 – 1.25], PMR = 5.75 x 10-4), portal vein 
thrombosis (ORMR = 2.51 [1.30-4.85], PMR = 6.31 x 10-3), right bundle branch block (ORMR = 1.68 [1.14 – 2.48], 
PMR = 8.51 x 10-3), myocardial infarction (ORMR = 1.12 [1.03 – 1.22], PMR = 1.09 x 10-2), atrioventricular block 
(ORMR = 1.24 [1.04– 1.47], PMR = 1.64 x 10-2), and reduced risk for hypertension (ORMR = 0.94 [0.89 – 0.98], PMR 
= 7.49 x 10-3) and cardiomyopathies (ORMR = 0.79 [0.68 – 0.91], PMR = 1.85 x 10-3) (Table S14). 
 
A GRK5 gain of function coding variant (p.Gln41Leu) leading to enhanced β-adrenergic receptor (βAR) 
desensitization of excessive catecholamine signaling has been proposed to provide a 'genetic β-blockade' that 
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improves survival in African Americans with heart failure 33. Functional studies have also shown β2-ARs can 
inhibit platelet aggregation and adhesion 34. In our study, this variant was not associated with thrombin 
reactivity (P = 0.51, data not shown). Having observed associations with multiple pathologic cardiopulmonary 
traits, we asked whether the GRK5 variant’s effect on platelet reactivity was modified by pharmacological β-
blockade. A small subset of Caerphilly participants were taking cardiac-specific, β1-AR selective (5.1%) or non-
selective drugs (3.1%) at the time platelet reactivity was measured. Fitting linear models with specific and non-
specific beta-blockers as additional covariates, we observed a negative interaction effect on platelet reactivity 
between the GRK5 variant and β1-AR selective drugs (ß = -0.60, SE = 0.24, P = 0.01) (Figure S3). 
 
To study the regulatory function of the GRK5 variant we next integrated cell type-specific epigenome maps 
derived from primary megakaryocyte cells 28; 29. The variant localizes to a region of open chromatin (DNAse 
hypersensitivity peak site) in a predicted enhancer region characterized by broad enrichment of active marks 
H3K27Ac and H3K4me1 (Figure 3A). Active enhancers are often characterized by short, unstable bi-directional 
transcripts termed enhancer RNAs (eRNAs). Integrating nascent transcription maps in K562 cells we observed 
the GRK5 variant localizes to the predicted TSS region of a eRNA 27 (Figure S4). Having observed multiple lines 
of evidence the variant is in an enhancer element, we asked whether the position was occupied by 
transcriptional regulators in vivo, as this could provide a clear testable mechanism of action in a non-coding 
DNA context. To this end, we scanned transcription factor (TF) binding datasets from mega-erythroid cell 
models generated by the ENCODE consortium 26. The variant position was bound by 27 factors, including the 
master hematopoietic transcription factor GATA1 in peripheral blood erythroblasts and the histone 
acetyltransferase p300 (MIM: 602700) in K562 cells (Table S15).  
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We verified binding of the GRK5 variant by GATA1 is also observed in primary MK cells 35 and 
hematopoietic stem/progenitor-derived erythroid precursors 36. The GATA1 binding motif is highly enriched at 
active eRNA in K562 cells 37. We next considered whether there was functional connectivity or association 
between the factors binding the GRK5 variant locus. Using the STRING algorithm we constructed a highly 
connected network model incorporating 24 of 26 mappable transcriptional regulators (Protein-Protein 
interaction enrichment p-value: < 1.0 x 10-16) (Figure 3B). Clustering of the network revealed several 
properties: SWI/SNF chromatin remodeling complex clustering with GATA1 (red cluster), transcriptional 
repressors (including one cluster of polycomb-related proteins) (green cluster), cAMP responsive factors (blue 
cluster), p300 and lineage factor IKZF1 (MIM: 603023) (khaki cluster), and NF-E2 (MIM: 601490) complex (light 
green cluster). These included p45 and MAFK (MIM: 600197), subunits of the heterodimeric NF-E2 complex 
required for megakaryocyte maturation and platelet production in vivo 38. Collectively, these results suggest 
the GRK5 non-coding variant affects platelet reactivity by modulating a functional megakaryocyte lineage 
enhancer, leading to platelet populations with altered GRK5 expression and function.  
 
We confirmed the locus drives enhancer activity in vitro by luciferase reporter assay, through binding of 
GATA1 and not through binding of GATA2 (Figure S5A-C). Enhancer activity in endogenous GATA1-expressing 
cells is largely abolished upon deletion of the GATA1 core binding motif (GATA1del Figure S5B). Given its close 
proximity to the GATA1 motif, we hypothesized the rs10886430-G could reduce the regulatory potential of the 
enhancer by interfering with binding of GATA1. Thus, we investigated the impact of the GRK5 variant on 
enhancer activity, both by targeted four-base deletion as well as single-base substitution of the minor “G” 
allele (Figure 4). In K562 cells introduction of the GRK5 variant effect allele (AtoGmut) repressed enhancer 
activity 1.5-fold (P < 0.001). Targeted deletion of the base position (AGTGdel) produced nearly identical results. 
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Endothelial HUVEC cells, which express lower levels of GATA1 (confirmed by qRT-PCR, data not shown), 
exhibited weak enhancer activity and a diminished capacity for the GRK5 variant effect allele to repress 
enhancer activity (1.3-fold, P < 0.05) (Figure 4). 
 
Having established a potential mechanism by which the DNA variant regulates GRK5 expression, we next 
investigated the role of GRK5 in platelet physiology. To this end we utilized iPSC-derived immortalized MK cell 
lines (imMKCLs) which produce functional platelets expressing cell markers CD42b (MIM: 606672)and VWF 
(MIM: 613160) 30. We first assessed the impact of reducing GRK5 expression in imMKCL by siRNA, achieving a 
knockdown efficiency of ~75% (Figure S6A). We performed platelet function testing of GRK5-depleted and 
control platelet progeny cells stimulated with agonists ADP/TRAP-6 by flow cytometry, measuring platelet 
surface activated GPIIb-IIIa (PAC1 antibody) and platelet surface P-Selectin (CD62P). Transient knockdown of 
GRK5 increased markedly the percentages of platelets positive for P-Selectin 1.6-fold (P < 0.05) and activated 
GPIIb-IIIa 1.2-fold (P < 0.05) (Figure 5A). The amounts of P-Selectin and activated GPIIb-IIIa exposed on the 
surface of each platelet, as judged by the geometric mean fluorescence intensity (MFI), were largely 
unchanged (Figure 5A). 
We next investigated the effect of repressing GRK activity on platelet function in the specific context of 
PAR1- or PAR4-activated signaling ex vivo via CCG215022, a pan-specific small molecule inhibitor exhibiting 
nanomolar IC50 values against both GRK2 (MIM: 109635) and GRK5. To this end, we performed platelet 
function testing on treated and control PRP stimulated with either TRAP-6 (PAR1 activator) or PAR4-AP by flow 
cytometry. Treatment with the GRK inhibitor increased the percentages of platelets positive for P-Selectin up 
to 2.3-fold in the presence of PAR4-AP but not TRAP-6 (Figure S6B). Given we observed activation in siRNA 
experiments upon ADP/TRAP-6 co-stimulation, the absence of an effect by PAR1 signaling alone in healthy 
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donor PRP treated with GRK inhibitor led us to consider whether stimulation with ADP alone would have an 
effect. We performed additional platelet function testing with a range of concentrations of TRAP-6, PAR4-AP, 
or ADP following GRK inhibition (Figure 5B, Figure S7). Significant increases in P-Selectin positive cells were 
again observed for PAR4-AP (20uM: 2.7-fold, P < 0.01), to a lesser extent ADP (1 uM: 1.2-fold, P < 0.05), but 
not TRAP-6 (Figure 5B, Figure S7). Since TRAP-6 activation may have been saturated at doses between 1 uM to 
20 uM, we ran independent experiments at lower doses of TRAP-6 in donor PRP (0.001 uM, 0.01 uM, 0.10 uM) 
and again found no effect of GRK inhibition on platelet activation (Figure S8). Together, these results suggest 
that inhibition of platelet GRK5 promotes PAR4-mediated platelet activation and to a lesser extent ADP-





In a GWAS of thrombin-induced platelet aggregation, we identify a GRK5 non-coding variant (rs10886430-G) 
strongly associated with increased reactivity to thrombin. We observed that thrombin-induced aggregation 
shares a common association signal at the GRK5 locus with three platelet cell indices (MPV, PLT, and PDW), 
the rs10886430 SNP being the shared causal variant in each case. Interestingly, the SNP had previously been 
identified as a sentinel variant positively associated with two indices: MPV and PDW 18 which are suggested by 
some as partial surrogates for platelet activation. Our study suggests a direct role for GRK5 in platelet 
activation, with an overall mechanism outlined in Figure 6. 
To determine the regulatory potential of the rs10886430 variant we first applied SMR to test for 
association between platelet gene expression and reactivity to thrombin. The analysis supported a model 
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whereby decreased GRK5 expression is associated with increased platelet reactivity through disruption by the 
rs10886430-G variant. The strong rs10886430-G eQTL for GRK5 replicated in two independent platelet 
datasets 17; 21 but none of the other 44 tissues in GTEx, 5 white blood cell subtypes or aortic endothelial cells 
indicating significant platelet specificity. Utilizing megakaryocyte and erythroid epigenetic datasets we found 
evidence for an active cell lineage enhancer at the SNP site bound by master hematopoietic transcription 
factor GATA1. GATA1 plays a critical role in megakaryocyte maturation and platelet formation in vivo 39. We 
supported the disruption of GRK5 expression by multiple experiments. We further investigated the role of 
GRK5 in platelet function using an iPSC-derived megakaryocyte and platelet production model. Knockdown of 
GRK5 by siRNA increased functional markers of platelet activation in agonist stimulated cells, including -
granule release (surface P-Selectin) and inside-out activation of the platelet integrin complex GPIIb-IIIa. These 
results indicate GRK5 plays an important functional role in negatively regulating thrombin-induced platelet 
reactivity.  
Thrombin is the most potent endogenous platelet activator and plays an important role in clot 
promotion and inhibition, and cell signaling, as well as additional processes that influence fibrinolysis and 
inflammation. The role of GRK5 could be mediated through several mechanisms. First, through canonical GRK 
GPCR desensitization of signal initiators PAR1 or PAR4 6. Second, GPCR desensitization of numerous 
downstream effectors of PAR signaling such as β2-AR (MIM: 107941) 34; 40, Akt (MIM: 164730), or the SRC 
family kinases 41. To further determine whether GRK5 affected PAR1 or PAR4 signaling, we conducted 
experiments that showed GRK5 inhibitory effects are mediated via inhibition of PAR4 driven platelet 
activation.  
PAR4 is involved in sustained platelet activation, and invokes sustained intracellular calcium response 
in platelets, phosphyltidylserine exposure, thrombin generation and fibrin deposition 13. Thus, PAR4 has been 
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suggested as a novel anti-platelet therapeutic target, with primate models and other studies indicating PAR4 
inhibition could provide superior inhibition with reduced bleeding diatheses 11; 12. Our results suggest that a 
significant genetically determinable fraction of the population could potentially receive greater benefit from 
PAR4 inhibition. Interestingly, a missense variant p.Ala120Thr in PAR4 has been described as affecting 
activation 42. However, this variant was not associated with full thrombin reactivity in our study (P=0.07, data 
not shown) and responses to a monoclonal antibody directed at PAR4 did not vary by genotype in another 
study 43. Taken together, this suggest that GRK5 variant rs10886430 may have stronger implications for 
thrombin-based platelet activation than the previously reported PAR4 coding variant. Our study does have 
some limitations. Given the modest sample size false negatives are expected. Since there are no other 
reported thrombin, PAR1 or PAR4 platelet reactivity GWAS we cannot yet assess replication of those findings.  
 Given the importance of thrombin in clot formation we used 2-sample MR to determine whether the 
genetic effect of the variant on platelet reactivity may play a putatively causal role in cardiovascular or 
cerebrovascular disease pathology. Whereas the role of platelets in arterial thrombosis is well established, our 
MR analysis utilizing the strong GRK5 instrumental variable also suggest thrombin-driven platelet reactivity 
contributes to the trajectory of venous thromboembolism (VTE), both in deep venous thrombosis (DVT) as 
well as pulmonary embolism (PE). Recently, the variant was independently tied to increased VTE risk in the 
INVENT Consortium and replicated in the Million Veteran’s Project 44. Critical for DVT propagation in vivo, 
platelets are recruited to developing venous thrombi where they support leukocyte accumulation and 
promote formation of procoagulant neutrophil extracellular traps 45. Markers of platelet activation are 
elevated in acute PE, correlate with the severity of right ventricular dysfunction, and can persist for several 
months 46. The contributing role of platelets in VTE is further supported by the observation that aspirin 
therapy reduces the risk of DVT and PE in patients undergoing orthopedic surgery 47. Thrombosis and excess 
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platelet activation are common pathological features of pulmonary arterial hypertension 48, another cause of 
pulmonary heart disease. While the etiologic heterogeneity characterizing ischemic stroke make it difficult to 
assign a causative role for platelet reactivity to any given subtype, the platelet content of embolized thrombi is 
twice that of in situ thrombi 49, suggesting the platelet aggregate increases propensity for embolization.  The 
importance of platelets in pathogenesis of acute MI is supported by both clinical and in vivo animal studies 
which show the initial thrombus (following endothelial injury) is primarily composed of activated platelets 50. 
In our investigation of the rs10886430-G variant among stroke subtypes available in MEGASTROKE we 
observed a markedly strong effect in prevalence of cardioembolic stroke, though not large vessel or small 
vessel disease. Compared to cardioembolic stroke, the large artery atherosclerosis and small vessel occlusion 
subtypes have vastly different etiologies 24.  MR analysis supported a causal role for thrombin-driven platelet 
reactivity specifically in the cardioembolic subtype. Causal associations with pulmonary embolism and 
cardioembolic stroke suggest the rs10886430-G variant is particularly enriched in emboli forming distally to 
the site of vascular occlusion. More broadly, our results underline the importance of thrombin-driven platelet 
reactivity in both venous and arterial disease. It remains to be seen whether rs10886430-G is an important 
variant to segment populations at risk relative to treatment for either venous or arterial disease. 
Beta-blockers are a common preventative therapy following MI and a mainstay for the management of 
heart failure 33. Functional studies have shown β2-ARs to inhibit platelet aggregation and adhesion through 
activation of platelet nitric oxide synthase 34. Given the role of GRK5 in desensitizing β-AR signaling we 
investigated whether the GRK5 variant’s effect on platelet reactivity was modified by beta-blocker therapy in a 
subset of Caerphilly participants. We observed a negative interaction effect on platelet reactivity between the 
GRK5 variant and β1-AR selective drugs and no effect with non-selective drugs. The absence of an appreciable 
effect with the latter may in part be explained by low sample sizes in the model (selective n = 56, non-selective 
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n = 34) as well as differences in chemistry which may affect platelet uptake 51. Future work could potentially 
examine the genotypic effect of the GRK5 variant on multiple drug classes in larger samples including direct 
thrombin inhibitors, beta-adrenergic blockers, and other anticoagulant and anti-platelet therapies. Over-
expression of cardiac GRK5 leads to early heart failure after pressure overload in mouse models 52. Also 
upregulated in human heart failure, GRK5 is being investigated as a therapeutic target with selective small 
molecule inhibitors under development 53. Our work highlights the potential for significant platelet-driven off-
target effects with this or other strategies seeking to inhibit GRK5. Notably, in platelet RNA-sequencing data 
GRK5 is by far the most expressed member of the GRK family. The next highest expressed GRK family 
members are GRK6 (MIM: 600869) (~18% expression level of GRK5) and GRK4 (MIM: 137026) (~2% expression 
level of GRK5), suggesting GRK5 is likely to be the critical protein family member active in platelets.54  Given 
the role of GRK5 in controlling PAR4-mediated platelet activation and the association of the rs10886430-G 
genetic effect on platelet reactivity with cardiovascular and cerebrovascular embolic events we suggest that 
finding a mechanism to maintain GRK5 activity in platelets could prove beneficial in preventing venous and 
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Figure Titles and Legends 
Figure 1. Regional and SNP associations of GRK5 with thrombin-induced platelet aggregation. A, Locus Zoom 
plot of the lead SNP (rs10886430) from genome-wide association analysis of thrombin-induced platelet 
aggregation in Caerphilly Prospective study (n = 1184). The plot depicts the 600-kb window flanking the 
rs10886430 (purple) variant which is located in the first intron of GRK5. B, Box plot of the effect of 
rs10886430-G variant dosage on thrombin-induced platelet aggregation (0.056 U/mL). Data points are plotted 
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as red circles. The bold horizontal line represents the median. The upper and lower hinges indicate the 25th 
and 75th percentiles, respectively. The whiskers extending from the hinges represent the values no further 
than 1.5 * interquartile range. 
 
Figure 2. GRK5 rs10886430-G is linked to platelet traits and causally effects platelet GRK5 expression and 
multiple cardiovascular disease outcomes. The rs10886430 variant regulates platelet cell traits, GRK5 platelet 
gene expression, as well as both cardiovascular and cerebrovascular disease pathologies. A, Heatmap of 
posterior probabilities from Bayesian colocalization analyses of thrombin reactivity and 5 blood cell traits in 
the 1.8 Mb LD block containing the rs10886430 variant (10q26.11). Shared SNP, probability of one shared SNP 
associated with both traits; Independent SNPs, probability of two independent SNPs associated with each 
trait; Trait 2 Only, probability of association with the blood cell trait and not with Thrombin-induced 
aggregation; Thrombin Only, probability of association with Thrombin-induced aggregation and not with the 
blood cell trait; No Association, probability of no association with either trait.  B, Manhattan plot depicting 
summary data-based Mendelian Randomization (SMR) analysis of association between platelet gene 
expression and platelet reactivity to thrombin (0.056 U/mL). C, Mendelian Randomization analysis of thrombin 
reactivity (rs10886430G instrument) and cardiopulmonary phenotypes in UK BioBank (Outcomes). Plotted are 
the OR of the causal estimates (circles) and associated 95% confidence intervals (error bars), color of circle 
indicates -log transformed P-value of estimate. Further description of medical outcomes codes and statistics is 
found in the Supplement and Table S12. 
 
Figure 3. GRK5 rs10886430 overlaps an active meta-erythroid lineage enhancer bound by interconnected 
factors. The rs10886430 variant resides in a megakaryocyte enhancer element. A, Epigenetic regulatory maps 
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of primary-derived MK and K562 cells. B, STRING Protein Network Analysis of DNA binding factors recruited to 
the rs10886430 variant in ENCODE mega-erythroid cell models. Proteins are represented as circles. Colors 
indicate network cluster membership. Solid lines indicate interactions within a network cluster. Dotted lines 
indicate interactions between proteins in different clusters. Line colors indicate type of evidence: cyan (known 
interaction from curated database), magenta (known interaction experimentally determined), yellow-green 
(text mining), black (co-expression). 
 
Figure 4. Mutagenesis causing deletion or rs10886430 A to G transition disrupts enhancer activity in 
multiple cell backgrounds. The rs10886430 variant modulates megakaryocyte enhancer activity. Top, diagram 
of GRK5 enhancer constructs: row 1, WT allele; row 2, four-base deletion including allele position; row 3, 
substitution with ‘G’ effect allele. Bottom, normalized luciferase activity in mega-erythroid K562 cells and 
endothelial HUVEC. Results are the mean of 3 independent experiments performed in quadruplicate (n 
total=12), error bars represent SEM. * P < 1 x 10-4, ** P < 5 x 10-5). 
 
Figure 5. Disrupting platelet GRK5 via siRNA or chemical inhibitor causes increased thrombin activation via a 
PAR4 receptor signaling process. GRK5 perturbation promotes platelet activation. A, Change in platelet 
activation markers P-Selectin and activated GPIIb-IIIa (PAC1) in response to 20 M ADP/TRAP6 stimulation 
(compared to untreated) following siRNA knockdown of GRK5 expression (or Green Fluorescent Protein (GFP) 
siRNA negative control) in imMKCL cells. Data represent mean +/- SEM of 4 independent experiments. 
Differences assessed by Student’s T-Test *, p < 0.05, **, p < 0.01. B, Change in P-Selectin in response to 
specific activation of either ADP, PAR1 (TRAP-6) or PAR4 (PAR4-AP) signaling (compared to untreated) 
following pharmacologic inhibition of GRK activity with 0.78 M CCG215022 (GRKi) or vehicle control (Con) in 
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PRP samples from healthy donors. Plotted data represent mean +/- SEM (n=3) difference in percentages of 
marker-positive platelets following treatment with the indicated concentrations of agonist. Differences 
between PRP treated with GRK inhibitor versus control assessed by Student’s T-Test *, p < 0.05, **, p < 0.01. 
 
Figure 6. Suggested mechanism of GRK5 regulatory variant in influencing PAR4 platelet activation and 
thrombosis risk. Schematic depicting the platelet-specific effects of GRK5 variant rs10886430 via a GATA1 
enhancer and modified suppression of platelet PAR4 signaling on thrombin activation. PAR4 has been studied 
as a drug target (BMS-986120). The model is supported by thrombin platelet reactivity association in PRP, a 
strong platelet eQTL in 2 independent samples, a lack of eQTL co-localization in other cells and tissues, 
mutagenesis and enhancer assays, siRNA and inhibitor (CCG215022) experiments in iPSC-derived 
megakaryocytes and platelets, and multiple population genetic studies for cardiovascular disease outcomes 
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